BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 27565504)

  • 1. Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation.
    Harada K; Yamada Y; Konishi T; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
    Int J Hematol; 2016 Dec; 104(6):709-719. PubMed ID: 27565504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Biosimilar Filgrastim for Cord Blood Transplantation: A Single-Institution Retrospective Analysis.
    Iino M; Yamamoto T
    Transplant Proc; 2018 Dec; 50(10):3804-3810. PubMed ID: 30577272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia.
    Elmaagacli AH; Basoglu S; Peceny R; Trenschel R; Ottinger H; Lollert A; Runde V; Grosse-Wilde H; Beelen DW; Schaefer UW
    Blood; 2002 Feb; 99(4):1130-5. PubMed ID: 11830457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia.
    Zheng C; Zhu X; Tang B; Yao W; Song K; Tong J; Geng L; Liu H; Sun Z
    Ann Hematol; 2015 Mar; 94(3):473-80. PubMed ID: 25217231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filgrastim following HLA-Identical Allogeneic Bone Marrow Transplantation: Long-Term Outcomes of a Randomized Trial.
    Ben Othman T; Ghedira H; Ben Abdejlil N; Lakhal A; Torjemane L; Ben Hamed L; Hamida S; Zouari B; Ladeb S
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2459-2465. PubMed ID: 30036571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience.
    Liu YC; Chang CS; Liu TC; Chen TP; Sue YC; Hsiao HH; Lin SF
    Kaohsiung J Med Sci; 2003 Nov; 19(11):541-8. PubMed ID: 14658482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.
    Chang YJ; Weng CL; Sun LX; Zhao YT
    Ann Hematol; 2012 Mar; 91(3):427-37. PubMed ID: 21789620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
    Schmitz N; Beksac M; Bacigalupo A; Ruutu T; Nagler A; Gluckman E; Russell N; Apperley J; Szerm J; Bradstock K; Buzyn A; Schlegelberger B; Matcham J; Gratwohl A
    Haematologica; 2005 May; 90(5):643-8. PubMed ID: 15921379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients.
    Auberger J; Clausen J; Kircher B; Kropshofer G; Lindner B; Nachbaur D
    Eur J Haematol; 2011 Dec; 87(6):531-8. PubMed ID: 21848700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.
    Schmitz N; Bacigalupo A; Hasenclever D; Nagler A; Gluckman E; Clark P; Bourquelot P; Greinix H; Frickhofen N; Ringdén O; Zander A; Apperley JF; Gorin C; Borkett K; Schwab G; Goebel M; Russell NH; Gratwohl A
    Bone Marrow Transplant; 1998 May; 21(10):995-1003. PubMed ID: 9632272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
    Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
    Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood stem cell transplantation compared with bone marrow transplantation from unrelated donors in patients with leukemia: a single institutional experience.
    Liu QF; Liu C; Zhang Y; Sun J; Yi ZS; Fan ZP; Xu D; Jiang QL; Xu XJ
    Blood Cells Mol Dis; 2010 Jun; 45(1):75-81. PubMed ID: 20382550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of clinical outcome between allogeneic peripheral blood stem cell transplantation and bone marrow transplantation].
    Wang M; Han M; Feng S
    Zhonghua Xue Ye Xue Za Zhi; 1999 Aug; 20(8):427-30. PubMed ID: 11721425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tbo-filgrastim versus filgrastim for stem cell mobilization and engraftment in autologous hematopoietic stem cell transplant patients: A retrospective review.
    Potter A; Beck B; Ngorsuraches S
    J Oncol Pharm Pract; 2020 Jan; 26(1):23-28. PubMed ID: 30854925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study.
    Targhetta C; Baronciani D; Capasso M; Depau C; Tandurella I; Giuseppina Corona M; Angelucci E
    Am J Hematol; 2016 Feb; 91(2):E7-8. PubMed ID: 26596244
    [No Abstract]   [Full Text] [Related]  

  • 18. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.